Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort
0301 basic medicine Oncology medicine.medical_specialty business.industry medicine.medical_treatment Hematology Immunotherapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oregovomab 030220 oncology & carcinogenesis Internal medicine Cohort medicine Epithelial ovarian cancer Nivolumab business medicine.drug